With an increasingly promising roster of approved cell therapies still burdened by complex manufacturing, multiple companies ...

CCRM and its CDMO subsidiary OmniaBio Inc., today announced an agreement with Avectas Limited ("Avectas") to evaluate its automated, integrated and scalable cell therapy manufacturing platform. The ...

DUBLIN--(BUSINESS WIRE)--The "Point-of-Care Cell and Gene Therapy Manufacturing Market - A Global and Regional Analysis: Focus on Technology, Therapeutic Area, End User, and Regional Analysis - ...

Chimeric antigen receptor (CAR) -T-cell therapies have yielded remarkable results in the treatment of hematological malignancies. Several autologous CAR T-cell products have received marketing ...

Ori Biotech's IRO platform has achieved an Advanced Manufacturing Technology designation from the FDA. The honor is extended to companies that show their technology can cut development timelines or ...

Automation, decentralized manufacturing, and supportive regulations are helping to surmount technical difficulties in cell and gene therapy manufacturing.

A roundtable discussion reveals how hybrid distributed models could provide a bridge from centralized cell-therapy ...

Pascal Touchon serves as global strategy advisor to RoslinCT and board director, bringing over four decades of international experience in the biopharmaceutical industry, combining operational ...

Cellares, an Integrated Development and Manufacturing Organization (IDMO) that combines automated manufacturing platforms with global Smart Factory infrastructure, and ProTgen, a therapeutic company ...

It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...

The alternative text for this image may have been generated using AI. Cellular gene therapies (CGTs) such as chimeric antigen receptor (CAR)-T cell and stem cell gene therapies are lifesaving for many ...